# Seventh Edition Staging 2017 Melanoma

Donna M. Gress, RHIT, CTR



### This webinar is sponsored by

#### The Centers for Disease Control and Prevention

Supported by the Cooperative Agreement Number DP13-1310

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



### Overview

- Provide key information for melanoma on
  - Common staging issues and questions
  - Exceptions and cautions for T, N, M
  - Diagnostic procedures vs. treatment
  - Treatment satisfying stage classification criteria
  - Blank vs. X



# Learning Objectives

- Analyze common staging issues and questions
- Determine exceptions and cautions for T, N, M
- Distinguish diagnostic procedures vs. treatment
- Identify treatment satisfying stage classification criteria
- Recognize difference between blank vs. X



# Melanoma Staging



# Clinical T Category

- Diagnostic biopsy to establish diagnosis and T category
- Determining thickness for T category
  - Must be measured by pathologist
  - Cannot use Clark level to infer thickness
- Mitosis required for T1 subcategories
  - May not assign T1a without mitosis
  - If ulceration present, mitosis not required for T1b
- Clark level not used in T category
  - Do not assign T based on Clark levels
  - Do not correlate Clark level with T category if thickness unavailable

# Clinical T Category

- Ulceration is NOT seen by physicians or patients
- Determining ulceration for T category
  - Never on physical exam, cannot be seen
  - Only by pathologist
  - Only determined by histopathological exam
- Direct extension not a factor in T category
  - Staging does not use extension into
    - Cartilage
    - Skeletal muscle
    - Bone
    - Other subcutaneous tissue



# Clinical N and M Categories

- Clinical N category assessment
  - Only based on physical exam and imaging
  - Biopsies are not allowed
- Clinical N subcategories
  - No subcategories of a or b assigned
  - N2c subcategory may be assigned
- N category criteria defined
  - Satellite tumors around a primary tumor
  - In transit tumors between primary tumor and nodal basin
- Clinical M category cautions
  - Need LDH for M1 subcategory
  - Must be distant skin and distant soft tissue for M1



# Pathologic T Category

- Do NOT use treatment information to change cT
- Definition of melanoma ulceration
  - Absence of completely intact epidermis above melanoma
  - Based only on histopathologic exam
- pT assignment uses all of the following
  - Use cT information
  - Operative findings
  - Resected primary tumor specimen
- Primary information for pT may come from clinical staging
  - Most if not all tumor may be removed in diagnostic biopsy
  - cT may be most of the information for pT assignment



# Pathologic N Category

- Micromets for N category
  - Only diagnosed microscopically on resected nodes
- Macromets for N category
  - Diagnosed clinically, confirmed microscopically on resected nodes
  - Nodal mets exhibit gross extracapsular extension
- Intralymphatic for N category: intransit and/or satellites
- Isolated tumor cells (ITC) considered positive nodes
- Stage group 0 or IA
  - Node microscopic evaluation not required
  - Assign cN0



# Pathologic M Category

- M category clarification
  - If microscopic proof, pM used
  - If no microscopic proof of any met site, cM use
- Multiple metastatic sites
  - Only one site must have microscopic proof to assign pM
  - All sites do not need microscopic proof to assign pM
- LDH unavailable
  - Must have LDH for M1 subcategory




### Criteria for Clinical Classification

- Patient undergoing diagnostic workup
  - Physical exam of primary site
  - Assessment of risk factors
  - Physical exam of potential regional nodes, no biopsies
  - Adequate biopsy to assess T category
    - Shave biopsy, incisional biopsy, or excisional biopsy
  - Imaging in higher T category or involved nodes
  - If distant mets are suspected
    - Imaging
    - LDH
  - Critical Clarifications: AJCC 7<sup>th</sup> Edition Melanoma Staging
- Rare incidental findings
  - Resections for other lesions do not meet surgical treatment criteria
  - Most incidental findings would be part of diagnostic workup

### Diagnostic vs. Treatment

- Diagnostic procedures
  - Excisional biopsy of lesion (pupil) to assess thickness (pupil or less)
  - Smaller biopsies may be needed for certain sites
  - Do NOT change staging based on subsequent info
- Surgical treatment of primary site
  - Resection with 1-2cm margin from tumor on all sides
    - Circle (iris) drawn around lesion (pupil) to establish boundaries
    - Draw football around circle to close wound
  - If nodal dissection not done, still considered treatment





# Treatment Satisfying Stage Classification

- Pathologic staging
  - Wide excision or re-excision of tumor
  - Nodal sampling or dissection
    - Sentinel nodes
    - Node dissection
    - Not required to qualify for staging
    - Not required for stage 0 or IA
  - Need LDH if distant metastasis are present
  - Critical Clarifications: AJCC 7<sup>th</sup> Edition Melanoma Staging
- Postneoadjuvant therapy staging
  - Clinical trials with chemotherapy and immunotherapy
  - NPCR: NO requirement for postneoadjuvant therapy staging
    - NPCR does NOT require or request submission of yp staging data
    - If neoadjuvant Rx, NPCR requires path stage group to be unknown



### Blank vs. X

- Tell patient's story through staging
- Clinical staging story of pt's diagnosis and workup
  - cTX = physician did not examine patient, inadequate biopsy
  - cT blank = registrar had no access to information
  - cT blank = no workup for pt, incidental finding at surgical treatment
- Pathologic staging pt's story through surgical treatment
  - pTX = someone lost specimen between OR and path dept
  - pT blank = pt didn't have surgical treatment
  - pT blank = registrar had no access to information



# Case Scenario



# Diagnostic Workup

#### **Case submitted by NPCR ETC**

- History/chief complaint
  - 78 year old male with long farming history referred to general surgeon for skin concerns
- Physical exam
  - Dark lesion on right upper extremity approximately 2x2cm
  - Golf ball sized soft tissue mass on right upper extremity
- Imaging
  - PET/CT: no findings of concern for metastases
- Procedure
  - No information provided on initial biopsy
- Pathology report
  - No pathology report on initial biopsy



# Clinical Staging Information

### Physical exam

- No information on arm primary lesion, need thickness
- Large soft tissue mass rt arm possible in transit mets

### Imaging

- No mets
- Unsure what area of body was scanned, no information provided

#### Procedure

- No information provided by registrar
- Biopsy is first step, needed to confirm melanoma
- Always need microscopic proof prior to extensive treatment

### Pathology report

No information provided by registrar



# Clinical Staging Answer & Rationale

#### cT blank

- No information on thickness, ulceration, or mitosis from registrar
- Physician would have information since this is standard of care

#### cN2c

Potential in transit mets

#### cM0

No signs or symptoms of mets

### Stage III

Any T with N category involvement, no distant mets



### **Treatment**

### History & physical

- 78 year old male, farming history indicates potential sun exposure
- 2x2cm dark lesion on arm, large soft tissue mass arm
- Lacking information on microscopic confirmation of diagnosis
- Physician must have information to plan treatment

### Operative report

- Wide local excision rt arm lesion, excision soft tissue arm mass, attempted sentinel node procedure
- Wide local re-excision for margins

### Pathology report

- Melanoma, Breslow 1.9mm, Clark's level IV, no surface ulceration
- Mitotic index 4/mm², no LVI or neurotropism, no satellites
- Extends focally to lateral margins, 0.5cm from deep margin
- In transit mets or node completely replaced, no nodes identified
- No residual tumor on re-excision, margins free



# Pathologic Staging Information

- Surgery
  - Patient had surgical resection qualifying for pathologic staging
- Clinical staging information
  - cT blank cN2c cM0
- Operative report
  - Dye injection did not identify nodes
- Pathology report
  - Melanoma, Breslow 1.9mm, no surface ulceration, no satellites
  - In transit mets or node completely replaces, no nodes identified
- Oncology consult
  - More than 2cm from primary, consistent with in transit mets



# Pathologic Staging Answer & Rationale


- pT2a
  - 1.9mm Breslow thickness
  - No ulceration
- pN2c
  - In transit mets
  - No nodes identified on sentinel node procedure
- cM0
  - No signs or symptoms of mets
- Stage IIIB



# Information and Questions on AJCC Staging



# Stage Classifications



### AJCC Web site

- https://cancerstaging.org
- Cancer Staging Education Registrar menu includes
  - Timing is Everything Stage Classifications
  - Critical Clarifications for Registrars
  - Disease Site Webinars
    - 5 sites: melanoma, lung, breast, prostate, colorectum
  - AJCC Curriculum for Registrars
    - 4 free self-study modules of increasing difficulty on staging rules
      - Each modules consists of 7 lessons, including recorded webinar with quizzes
  - Presentations
    - Self-study or group lecture materials, including blank vs. X





### **AJCC** Web site


- https://cancerstaging.org
- Cancer Staging Education Physician menu includes
  - Articles
    - 18 articles on AJCC 7<sup>th</sup> edition staging in various medical journals
  - Webinars
    - 14 free webinars on 7<sup>th</sup> edition staging rules and some disease sites
- Cancer Staging Education General menu includes
  - Staging Moments
    - 15 case-based presentations in cancer conference format to promote accurate staging with answers and rationales



# AJCC Cancer Staging Manual and Atlas







Order at http://cancerstaging.net



### **CAnswer Forum**

- Submit questions to AJCC Forum
  - Located within CAnswer Forum
  - Provides information for all
  - Allows tracking for educational purposes







# Summary



### Summary

- Employ critical thinking to understand disease site
  - Analyze common staging issues affecting stage assignment
  - Determine exceptions and cautions for T, N, M
  - Utilize guidelines available to registrars
- Tell patient's story through accurate staging
  - Utilize correct stage classifications
  - Distinguish diagnostic procedures vs. treatment
  - Identify treatment satisfying stage classification criteria
  - Recognize difference in story between blank vs. X
- Identify resources for AJCC staging



# Thank you

**Donna M. Gress, RHIT, CTR**AJCC Technical Specialist



American Joint Committee on Cancer
633 N. Saint Clair, Chicago, IL 60611-3211
Validating science. Improving patient care.

cancerstaging.org



Upcoming Webinar

Seventh Edition Staging 2017

Colorectum Cancer August 24, 2017

Q&A from Registry Visits
September 14, 2017



### This webinar is sponsored by

### The Centers for Disease Control and Prevention

Supported by the Cooperative Agreement Number DP13-1310

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

